Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Celgene Corp. (NASDAQ: CELG).

Full DD Report for CELG

You must become a subscriber to view this report.


Recent News from (NASDAQ: CELG)

Celgene Corporation (CELG) CEO Mark Alles on Citi's 13th Annual Biotech Conference (Transcript)
Celgene Corporation (CELG) Citi's 13th Annual Biotech Conference Call September 6, 2018 12:00 PM ET Executives Mark Alles - Chairman and Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Analysts Robyn Karnauskas - Citigroup Presen...
Source: SeekingAlpha
Date: September, 06 2018 19:05
Will Revlimid's Patent Protection Hold Up For Celgene?
Revlimid Patent Litigation Key Issue That Is Clouding Stock Celgene is facing a similar situation to AbbVie, the last company that I recently wrote on - a significant portion of revenue tied up in one drug, and the potential for upcoming generic competition if the company's patents do ...
Source: SeekingAlpha
Date: September, 05 2018 14:39
Abivax UC candidate shows positive action in mid-stage study
A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,...
Source: SeekingAlpha
Date: September, 05 2018 12:17
Agios Pharma and Celgene terminate partnership developing AG-881
Agios Pharmaceuticals (NASDAQ: AGIO ) and Celgene (NASDAQ: CELG ) have mutually agreed to terminate their collaboration and license agreement inked on April 27, 2015, to develop and commercialize products containing pan-IDH inhibitor AG-881. More news on: Agios Pharmaceuticals, Inc., Cel...
Source: SeekingAlpha
Date: September, 05 2018 07:39
Sutro Biopharma Begins U.S. IPO Effort
Quick Take Sutro Biopharma ( STRO ) intends to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1 registration statement . The clinical stage biopharmaceutical company develops protein cancer therapeutics by using OCFS protein synthesis technology. STRO is ...
Source: SeekingAlpha
Date: September, 04 2018 13:40
Today's Research Reports on Trending Tickers: Amarin and Celgene
NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Major U.S. equities closed mostly higher on Friday and posted upbeat performance for the week. Market volatility source have been coming from U.S. and international trade partners, as the U.S. Trade Representative’s office said that &#x...
Source: ACCESSWIRE IA
Date: September, 04 2018 08:00
Acceleron's Luspatercept: IOMachine Focused On NDA
On TPT member request, we ran Acceleron Pharma ( XLRN ) through the IOMachine , July 2nd 2018. If you recall, the IOMachine (Copyright applied: please do not copy) performs a four-factor test on a stock and comes up with a buy/sell investibility opinion. These four factors are upcoming cataly...
Source: SeekingAlpha
Date: September, 03 2018 08:00
Why Darzalex Is Growing Faster Than Revlimid, Particularly Outside The U.S.
As populations age and multiple myeloma becomes more prevalent, sales of Celgene's ( CELG ) Revlimid and Johnson & Johnson's ( JNJ ) Darzalex are both growing, but Darzalex is growing faster. The growth of Darzalex relative to that of Revlimid is even faster outside than in the US. Left ...
Source: SeekingAlpha
Date: September, 03 2018 04:10
Celgene Vs. AbbVie: The 2 Cheapest Large Cap Pharma Stocks
Celgene ( CELG ) and AbbVie ( ABBV ) are the two fastest growing large-cap pharma stocks. Both companies are heavily reliant on one drug, Revlimid for Celgene and Humira for AbbVie. Even considering concentration risk for each, I consider both as good buys right now, but I'd give the slight ed...
Source: SeekingAlpha
Date: August, 31 2018 17:48
Your Cancer Highlight: Just How Far Can Karyopharm Go?
As discussed last week, the treatment space of multiple myeloma is brimming with competition, which is only stiffening as key players enter the arena. One of those key players is Karyopharm (KPTI), which is developing an intriguing targeted therapy that blocks a process called "nuclear expor...
Source: SeekingAlpha
Date: August, 30 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0889.5990.4690.5088.563,622,110
2018-05-1781.0879.9881.2279.1510,246,824
2017-12-29104.27104.36105.36104.154,500,810
2017-12-28104.74104.75105.5747104.083,927,803
2017-12-27106.57104.46107.209104.105,967,386

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-13301,0471,129,93426.6429Cover
2018-12-12269,0221,165,28023.0865Cover
2018-12-11292,1571,723,52716.9511Cover
2018-12-10282,0541,568,32117.9845Cover
2018-12-07313,2051,216,84425.7391Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CELG.


About Celgene Corp. (NASDAQ: CELG)

Logo for Celgene Corp. (NASDAQ: CELG)

Not available

 

Contact Information

 

 

Current Management

  • Robert J. Hugin / CFO

Current Share Structure

  • Market Cap: $59,421,326,724 - 05/15/2018
  • Issue and Outstanding: 724,827,113 - 04/23/2018

 


Recent Filings from (NASDAQ: CELG)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 04 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 04 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 06 2018
Amendment to a previously filed SC TO-T
Filing Type: SC TO-T/AFiling Source: edgar
Filing Date: March, 05 2018

 

 


Daily Technical Chart for (NASDAQ: CELG)

Daily Technical Chart for (NASDAQ: CELG)


Stay tuned for daily updates and more on (NASDAQ: CELG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CELG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CELG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CELG and does not buy, sell, or trade any shares of CELG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/